Cindy Cunningham
Psychiatric/Mental Health · Dover, DENPI 1447277207
Payments from drug & device makers
Across 650 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$1K
- plus $6K from 21 others
What the payments were for
- Food & beverage$13,83097%
- Education$4423%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 65 | $1,626 |
| Johnson & Johnson | 68 | $1,574 |
| Otsuka America Pharmaceutical, Inc. | 56 | $1,535 |
| Teva Pharmaceuticals USA, Inc. | 55 | $1,353 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 50 | $1,347 |
| Lundbeck LLC | 67 | $1,142 |
| Neurocrine Biosciences, Inc. | 53 | $1,024 |
| AbbVie | 57 | $965 |
| Axsome Therapeutics, Inc. | 25 | $886 |
| Corium, LLC | 39 | $845 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $545 |
| Sunovion Pharmaceuticals Inc. | 16 | $259 |
| Vanda Pharmaceuticals Inc. | 12 | $233 |
| Supernus Pharmaceuticals, Inc. | 11 | $166 |
| Ironshore Pharmaceuticals Inc. | 8 | $160 |
| E.r. Squibb & Sons, L.L.C. | 6 | $130 |
| Tris Pharma Inc | 8 | $115 |
| Idorsia Pharmaceuticals US Inc | 6 | $94 |
| Indivior Inc. | 5 | $84 |
| Biogen | 2 | $45 |
| Avanir Pharmaceuticals, Inc. | 3 | $43 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $17 |
| Neuronetics, Inc. | 1 | $16 |
| Braeburn Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,375
- CAPLYTA$487
- ARISTADA$480
- Auvelity$374
- INGREZZA$361
- REXULTI$347
- INVEGA$267
- ABILIFY MAINTENA$248
- AUSTEDO$244
- INVEGA SUSTENNA$234
- INVEGA TRINZA$234
- ABILIFY ASIMTUFII$123
- ARISTADA INITIO$120
- VRAYLAR$120
How this compares
$14,272 in reported general payments places this provider in the 95th percentile of 177 psychiatric/mental health providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 12 | $83,398 |
| Invega SustennaPaliperidone Palmitate | 24 | $67,483 |
| RexultiBrexpiprazole | 34 | $63,761 |
| VraylarCariprazine Hcl | 31 | $56,744 |
| Abilify MaintenaAripiprazole | 19 | $47,908 |
| TrintellixVortioxetine Hydrobromide | 34 | $25,755 |
| VyvanseLisdexamfetamine Dimesylate | 35 | $13,829 |
| Lurasidone Hcl | 35 | $12,883 |
| Aripiprazole | 196 | $7,403 |
| Quetiapine Fumarate | 279 | $5,378 |
| Bupropion XlBupropion Hcl | 245 | $5,063 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 123 | $3,860 |
| Hydroxyzine Hcl | 128 | $3,764 |
| Trazodone Hcl | 240 | $3,721 |
| Asenapine Maleate | 15 | $3,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $1,574 | $150,88136 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,535 | $111,66953 claims |
| AbbVieVraylar | $965 | $56,74431 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $545 | $39,58469 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 psychiatric/mental health providers in Delaware.
Other psychiatric/mental health in Dover
- Ericka Taylor-DanielDover$39K
- Jeremy LegatesDover$3K
- Melchizedec BosireDover$3K
- Sherri ClarkDover$3K
- Maureen DarlingDover$3K
- Heather FryeDover$3K
- Morgan WebbDover$2K
- Ronald TyreeWilmington$59K
- Kameka HartNewark$10K
- Jenika MilesWilmington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.